期刊文献+

患者依从性与华法林抗凝出血并发症分析 被引量:7

The Analysis of the Correlation Between Patient Obedience and Warfarin Anticoagulation Bleeding Complications
下载PDF
导出
摘要 目的探讨从患者因素提高口服华法林抗凝出血的安全性。方法收集2005年1月—2011年10月该院收治的115例因各种原因引起的动静脉血栓病需长期口服华法林抗凝病人记录1年并发症,根据患者完全、部分、无依从性分3组,分别分析其并发症的发生。结果依从性好于坏影响患者出血并发症发生率。结论长期口服华法林抗凝病人须严格遵照医生医嘱进行随访、监测INR监测及调整用量,以确保安全防止并发症发生。 Objective To study how to increase the safety of oral warfarin auticoagulation from the aspect of patients. Methods 115 cases of patients who had arterial and venous thrombosis caused by various reasons and needed long-term oral warfarin anticoagulation from January, 2005 to October, 2011 were selected as the subjects. The complications occurred in one year of them were recorded. They were divided into 3 groups according to the degree of their obedience, complete obedience patients group, partial obedience patients group and no obedience patients group. The reasons that caused the disease of the g^oups were analyzed respectively. Results Good or bad obedience of patients influence the incidence of bleeding complications. Conclusion Long-term oral warfarin anticoagulant patients should strictly follow the doctor's orders for follow-up, monitor INR and adjust the dosage so as to ensure the safety of the patients and prevent the incidence of complications.
作者 刘永东
出处 《中外医疗》 2013年第29期25-25,27,共2页 China & Foreign Medical Treatment
关键词 依从性 华法林 出血并发症 Obedience Warfarin Bleeding complications
  • 相关文献

参考文献3

二级参考文献37

  • 1Butchart EG, Li HH, Payne N, et al. Twenty years'experience with the Medtronic Hall valve [ J]. J Thorac Cardiovasc Surg, 2001, 121: 1090- 1100.
  • 2Aagaard J, Tingleff J, Hansen CN, et al. Twelve years' clinical experience with the CarboMedics prosthetic heart valve [ J ]. J Heart Valve Dis, 2001, 10: 177- 184.
  • 3Salem DN, Stein PD, A1 - Ahmad A, et al. Antithrombotic therapy in valvular heart disease- - native and prosthetic: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy [ J ]. Chest, 2004, 126: 457-482.
  • 4Baglin TP, Keeling DM, Watson HG. Guidelines on oral anticoagulation (war- farin) : thind edition - 2005 update [J]. Br J Haenaatol, 2006, 132: 277-285.
  • 5Moil T, Asano M, Ohtake H, et al. Anticoagulant therapy after prosthetic valve replacement- optinml PT- INR in Japanese patients [J]. Ann Thorac Cardiovasc Surg, 2002, 8: 83-87.
  • 6You JH, Chan FW, Wong RS, et al. Is INR between 2.0 and 3.0 the optimal level for Chinese patients on warfarin therapy for moderate- intensity antieoagulation.9 [ J ] Br J Clin Phannaeol, 2005, 59 (5): 582-587.
  • 7Hirsh J, Fuster V, Ansell J, et al. American Heart Association/American Col- lege of Cardiology Foundation guide to warfarin therapy [ J ]. J Am Coil Cardiol, 2003, 41 (9) : 1633- 1652.
  • 8David MW, Chang P, David LA, et al. Comparison of plasma prothrombin and factor Ⅶ and urine prothrombin F1 concentration in palients on longterm warfarin therapy and those in the initial phase [ J ]. Am Hematol, 1998, 57:193- 199.
  • 9Ferreira CN, Vieira LM, Dusse LM, et al. Evaluation of the marker of hypercoagulability prothrombin fragment F 1 + 2 in patients with mechanical or biological heart valve prostheses [ J ]. Arq Bras Cardiol, 2002. 79 (5): 501-509.
  • 10Sakata T, Kario K, Matsuo T, et al. Suppression of plasma - activated factor levels by warfarin therapy [J]. Arterioscler Thromb Vasc Biol, 1995, 15 (2): 241- 246.

共引文献176

同被引文献66

  • 1周自强,胡大一,陈捷,张仁汉,李奎宝,赵秀丽.中国心房颤动现状的流行病学研究[J].中华内科杂志,2004,43(7):491-494. 被引量:1401
  • 2孟旭,李金钟,刘岩,张海波.人工机械瓣膜置换术后口服抗凝药的抗凝治疗强度标准[J].中华心血管病杂志,2004,32(7):618-621. 被引量:58
  • 3Kayali MT, Fetieh MW, Abdulsalam MA, et al. Thrombotic Obstruction of Bileaflet Mechanical Prosthetie Heart Valves~ Early Diagnosis and Management [J~. J Cardiovasc Surg (Tori- no), 1998, 39(3): 400-411.
  • 4Butchart EG, Lewis PA, Bethel JA, et al. Adjusting Anticoag- ulation to Prosthesis Thromhogenicity and Patient Risk Factors Recommedations for the Medtronic Hall Valve [J~. Circulation, 1991, 84(5): 61-69.
  • 5Kalaria VG, Passannante MR, Shah T, et al. Effect of Mitral Re- gurgitation on Left Vent ricular Throm bus Formation in DilatedCardiomyopathy ['J]. Am Heart J, 1998, 135(2) ~ 215-220.
  • 6Michael OC. Anticoagulation in the Ambulatory Patien% Basic Principles and Current Concepts in Warfarin Therapy E]~. Top- ics in Geriatric Rehabilitation, 2001, 17(2): 18-37.
  • 7Mackay JW, Fenech ME, Myint KS. Acute rhabdomyolysis caused by combination therapy with atorvastatin and warfarin I-J]. Br J HospMed(Lond),2012,73(2) : 106-107.
  • 8Kontozis L, Skudieky D, Hopley MJ, et al. Long term Follow up of St. Jude Medical Prosthes is in a Young Rheumatic Popu- lation Using Low level Warfarin Anticoagulation: an Analysis of the Temporal Distribution of Causes of Death EJ]. Am J Cardi- ol, 1998, 81(6): 736-739.
  • 9Levine MN, Hirsh J, Landefeld S, et al. Hemorrhagic complica- tions of anticoagulant treatment [J]. Chest, 1992,102 : 325-363.
  • 10Shuen AY,Wong BY,Fu L, et al. Evaluation of the warfarin- resistance polymorphism,VKORC1 Asp36Tyr, and its effect on dosage algorithms in a genetically heterogeneous anticoagulant clinicEJ~. Clin Biochem,2012, 45(6) :397-401.

引证文献7

二级引证文献53

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部